TY - JOUR T1 - The benzenesulfoamide T0901317 is a novel RORα/γ Inverse Agonist JF - Molecular Pharmacology JO - Mol Pharmacol DO - 10.1124/mol.109.060905 SP - mol.109.060905 AU - Naresh Kumar AU - Laura A Solt AU - juliana J Conkright AU - Yongjun Wang AU - Monica A Istrate AU - Scott A Busby AU - Ruben Garcia-Ordonez AU - Thomas P Burris AU - Patrick R Griffin Y1 - 2009/11/03 UR - http://molpharm.aspetjournals.org/content/early/2009/11/03/mol.109.060905.abstract N2 - Retinoic acid receptor-related orphan receptors (RORs) regulate a variety of physiological processing including hepatic gluconeogenesis, lipid metabolism, circadian rhythm and immune function. Here we present the first high affinity synthetic ligand for both RORα and RORγ. In a screen against all forty-eight human nuclear receptors, the benzenesulfoamide LXR agonist T0901317 inhibited transactivation activity of RORα and RORγ but not RORβ. T0901317 was found to directly bind to RORα and RORγ with high affinity (Ki 132 nM and 51 nM, respectively) resulting in modulation of the receptor's ability to interact with transcriptional cofactor proteins. T0901317 repressed RORα/γ-dependent transactivation of ROR responsive reporter genes and in HepG2 cells reduced recruitment of the coactivator SRC2 by RORα at an endogenous ROR target gene. Using siRNA, we demonstrate that repression of the gluconeogenic enzyme glucose-6-phosphatase in HepG2 cells by T0901317 is ROR-dependent and not due to the compound's LXR activity. In summary, T0901317 represents a novel chemical probe to examine RORα/γ function and an excellent starting point for development of ROR selective modulators. More importantly, our results demonstrate that small molecules can be used to target the RORs for therapeutic intervention in metabolic and immune disorders.The American Society for Pharmacology and Experimental Therapeutics ER -